KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $106.2 million.

  • Amneal Pharmaceuticals' Free Cash Flow fell 1496.21% to $106.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.3 million, marking a year-over-year decrease of 71.37%. This contributed to the annual value of $243.2 million for FY2024, which is 1957.46% down from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Free Cash Flow stood at $106.2 million, which was down 1496.21% from $61.0 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Free Cash Flow ranged from a high of $136.4 million in Q1 2021 and a low of -$130.6 million during Q2 2022
  • Its 5-year average for Free Cash Flow is $48.4 million, with a median of $69.7 million in 2023.
  • Its Free Cash Flow has fluctuated over the past 5 years, first crashed by 17595.22% in 2022, then soared by 46238.56% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Free Cash Flow stood at $45.8 million in 2021, then crashed by 175.95% to -$34.8 million in 2022, then surged by 462.39% to $126.0 million in 2023, then decreased by 18.29% to $102.9 million in 2024, then increased by 3.14% to $106.2 million in 2025.
  • Its last three reported values are $106.2 million in Q3 2025, $61.0 million for Q2 2025, and -$5.8 million during Q1 2025.